Effective cardioprotection through strict blood pressure control in type 2 diabetic patients: An analysis of recent antihypertensive intervention studies (1996-2002);Analyse von aktuellen interventionsstudien (1996-2002): Erfolgreiche kardioprotektion durch aggressive antihypertensive therapie bei patienten mit typ-2-diabetes

Diabetes und Stoffwechsel

Volumn 12, Issue 3, 2003, Pages 153-165

  Schernthaner, G ^a,b  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^b 1 Medizinischen Abteilung   (Austria)

Author keywords

Antihypertensive treatment; Blood pressure; Cardioprotection; Type 2 diabetes

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOSARTAN; NIFEDIPINE; RAMIPRIL; THIAZIDE DIURETIC AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC ANGIOPATHY; DRUG EFFECT; HEART PROTECTION; HUMAN; HYPERTENSION; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SYSTOLIC HYPERTENSION; TREATMENT OUTCOME;

EID: 0345255145     PISSN: 09420037     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D for the Multiple Risk Factor Intervention Trial Group: Diabetes, other risk factors and 12-year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 16 (1993) 434-444
2. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH: A prospective study of maturity-on-set diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151(1991) 1141-1147
3. Haffner STM, Lehto S, Rönnemaa T, Pyörälä KM, Laakso M: Mortality from coronary heart disease in subjects with type-2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N.Engl.J.Med. 339 (1998) 229-234
4. Hu FB, Stampfer MJ, Solomon CG, Liu S, Willett C, Speizer FE, Nathan DM, Manson JE: The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women. Arch. Intern Med. 161 (2001) 1717-1723
5. Lotufo PA, Gaziano JM, Chae CU, Ajani UA, Moreno-John G, Buring JE, Manson JE: Diabetes and all-cause and coronary heart disease mortality among US male physicians. Arch.Intern Med. 161 (2001) 242-247
6. Goraya TY, Leibson CL, Palumbo PJ, Weston SA, Kilian JM, Pfeifer EA, Jacobsen STJ, Frye RL, Roger VL: Coronary athersclerosis in diabetes mellitus. A population-based autopsy study. J Am Coll Cardiol 40 (2002) 948-952
7. Vaccarino V, Parsons L, Every NR, Barton HV, Krumholz HM: Sex-based differences in early mortality after myocardial infarction. National Registry of Myocardial Infarction 2 Participants. N.Engl.J.Med. 341 (1999) 217-225
8. Meisinger C, Thorand B, Schneider A, Stieber J, Doring A, Lowel H: Sex differences in risk factors for incident type 2 diabetes mellitus: the MONICA Augsburg cohort study. Arch Intern Med 162 (2002) 82-89
9. Norhammer A, Tenerz A, Hamsten A, Efendic S, Ryden L, Malmberg K: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 359 (2002) 2140-2144
10. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, Currier JW: Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94 (1996) 1818-1825
11. Herlitz J, Wognsen GB, Karlson BW, Sjoland H, Karlsson T, Caidahl K, Hartford M, Haglid M: Mortality, mode of death and risk indicators for death during 5 years after coronary artery bypass grafting among patients with and without a history of diabetes mellitus. Coron Artery Dis 11 (2000) 339-346
12. Löwel H, Koenig W, Hörmann A, Keil U: The impact of diabetes mellitus on survival after myocardial infarction: can it be modified by drug treatment? Results of a population-based myocardial infarction register follow-up study. Diabetologia 43 (2000) 218-226
13. Van Belle E, Perle M, Braune D, Chmait A, Murice TH, Kaveh A, McFadden EP, Bauters CH, Lablanche JM, Bertrand ME: Effects of coronary stenting on vessel patency and long-term clinical outcome after percutaneous coronary revascularization in diabetic patients. J Am Coll Cardiol 40 (2002) 410-417
14. Mathew V, Holmes DR. Outcomes in diabetics undergoing revascularization. J Am Coll Cardiol 40 (2002) 424-427
15. Carson JL, Scholz PM, Chen AY, Peterson ED, Gold J, Schneider STH: Diabetes mellitus increases short-term mortality and morbidity in patients with undergoing coronary artery bypass graft surgery. J Am Coil Cardiol 40 (2002) 418-423
16. Woodfield SL, Lundergan CF, Reiner JS, Greenhouse W, Thompson MA, Rohrbeck SC, Deychak Y, Simoons ML, Califf RM, Topoi EJ, Ross AM: Angiographic findings and outcome in diabetic patients treated with thrombolytic therapy for acute myocardial infarction: the GUSTO-I experience. J Am Coll Cardiol 28 (1996)1661-1669
17. Nichols GA, Erbey JR, Hillier TA, Brown JB: Congestive heart failure in type-2 diabetes. Diabetes Care 24 (2001) 1614-1619
18. Rutter MK, Wahid ST, McComb JM, Marshall SM: Significance of silent ischemia and micro-albuminutia in predicting coronary events in asymptomatic patients with type-2 diabetes. J Am Coll Cardiol. 40 (2002) 56-61
19. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
20. Aromaa A, Reunanen A, Pyorala K: Hypertension and mortality, in diabetic and non-diabetic Finnish men. J Hypertens Suppl 2 (1984) S205-207
21. Schernthaner G: Arterielle Hypertonie und Diabetes mellitus. Teil 1: Interventionsstrategien zur kardiovaskulären Protektion. Diabetes und Stoffwechsel 5 (1996) 223-232
22. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH Stamler J: Effect of diuretic-based Antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276 (1996) 1886-1892
23. UK Prospective: Diabetes Study (UKPDS) Group: Tight blood pressure control and risk of macrovascular and microvascular complication in type-2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
24. Hansson L, Liudholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 353 (1999) 611-616
25. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramiptil on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
26. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius St, Menard J, Rahn KH, Wedel H, Westerling for the HOT Study Group: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal re sults of the hypertension optimal treatment (HOT) randomised trial. Lancet 351 (1998) 1755-1762
27. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ, Fletcher AE, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R: Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N.Engl. J.Med 340 (1999) 677-684
28. Lindholm LH, Hansson L, Ekbom T, Dahiof B, Lanke J, Linjer E, Schersren B, Wester BO, Hedner T, de Faire U: Comparison of antihypertensive treatments in preventing cardiovascular events in elderly diabetic patients: results from the Swedish Trial in Old Patients with Hypertension-2. J Hypertens 18 (2000) 1671-1775
29. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): Major cardiovascular events in hypertensive patients randomized to Doxazosin vs Chlorthalidone. JAMA 283 (2000) 1967-1975
30. Barzilay JI, Jones CL, Davis BR, Basile JN, Goff DC, Ciocon JO, Sweeney ME, Randall OS: Baseline Characteristics of the Diabetic Participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 24 (2001) 654-658
31. Major Outcomes in High-Risk Hypertensive Patients randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs. Diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 (2002) 2981-2997
32. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM: Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blokker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment (INSIGHT). Lancet 356 (2000) 366-372
33. Hansson L, Hedner T, Lund-Johansen P, Kjeldsen SE, Lindholm LH, Syvertsen JO, Lanke J, de Faire U, Dahlöf B, Karlberg BE: Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet 356 (2000) 359-365
34. Lindholm LH, Ibsen H, Dahlöf B, Devereux RB, Beevers G, De Faire U, Fyhrquist F, Julius ST, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn ST: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
35. UK Prospective Diabetes Study (UKPDS) Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type-2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
36. Dahlöf B, Devereux RB, Kjeldsen SE, Julius ST, Beevers G, De Faite U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedetsen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
37. Brenner BM, Cooper ME, De Zeeuw D, Keane WF, Mitch WE, Parving H-H, Remuzzi G, Snapinn SIM, Zhang Z, Shahinfar S, for the RENAAL Study Investigators. N Engl J Med 345 (2001) 861-869
38. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, for the Collaborative Study Group: Renoprotective effect of the angiotensin-receptor antagonist Irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
39. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
40. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH: Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 51 (2002) 1157-1165
41. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38 (2001) E28-32
42. Schernthaner G: Antihypertensive Therapy. In: Textbook of Type 2 Diabetes. Eds. Goldstein B.J. & Müller-Wieland. Martin Dunitz Publishers. London (2003) 29.1-29.16
43. Blood pressure lowering treatment Trialists Collaboration: Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: resuits of prospectively designed overviews of randomised trials. The Lancet 356 (2000) 1955-1964
44. Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Cavazzini CH, Furberg CD: Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapy: a meta-analysis of tandomised controlled trials. Lancet 356 (2000) 1949-1954
45. Schnack CH, Hoffmann W, Hopmeier P, Schernthaner G: Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria. Diabetologia 39 (1996) 1611-1616
46. Klauser R, Prager R, Gaube S, Gisinger C, Schnack C, Kuenburg E, Schetnthaner G: Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus. Hypertension 17 (1991) 15-21
47. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: N Engl J Med 342 (2000) 905-912
48. Exner DV, Dries DL, Domanski MJ, Cohn JN: Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med 344 (2001) 1351-1357
49. Fuller JH, Shipley MJ, Rose G, Jartett RJ, Keen H: Mortality from coronary heart disease and stroke in relation to degree of glycaemia: the Whitehall study. Brit Med. J. 287 (1983) 867-870
50. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344 (2001) 1343-1350
51. Knowler WC, Barrett-Connot E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. Diabetes Prevention Program Research Group. N Engl J Med 346 (2002) 393-403
52. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: STOP-NIDDM Trail Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359 (2002) 2072-2077
53. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities. The role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 (1996) 374-381
54. DeFronzo RA, Ferrannini E: Insulin resistance - a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atheroslerotic disease. Diab.Care 14 (1991) 173-194
55. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B: HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 286 (2001) 1882-1885
56. Grossmann E, Messerli FH, Goldbourt U: High blood pressure and diabetes mellitus. Are all antihypertensive drugs created equal. Arch Intern Med 160 (2000) 2447-2452
57. Brown MJ, Castaigne A, De Leeuw PW et al.: Influence of diabetes and type of hypertension on the response to antihypertensive treatment. Hypertension 35 (2000) 1038-1042
58. 1999 WHO/ISH Guidelines for the Management of Hypertension Guidelines Subcommittee WHO - International Society of Hypertension. J. Hypertens. 17 (1999) 151-183
59. Adler AI, Stratton M, Neil HAW, Yudkin JS, Mattews DR, Cull CA, Wright AD, Turner RC, Holman RR on behalf of the UK Prospective: Association of systolic blood pressure with macrovascular complications of type-2 diabetes (UKPDS 36): prospective observational study. BMJ 321 (2000) 412-419
60. Schrier RW, Estacio RO, Esler A, Mehler P: Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Internal 61 (2002) 1086-1097